Medications

Bempedoic acid improves outcomes in statin-intolerant patients

The cholesterol-lowering drug bempedoic acid reduced the combined rate of major adverse cardiovascular events by 13%, meeting its primary endpoint in a large study of patients with high cholesterol who were unable to tolerate ...

Cardiology

Long-term outcomes of PCI, CABG compared for multivessel CAD

For patients with multivessel coronary artery disease, the rates of major adverse cardiac events and safety events do not differ for those receiving percutaneous coronary intervention (PCI) with everolimus-eluting stent or ...

page 1 from 13